Biogen expected to name Michel Vounatsos as new CEO

CAMBRIDGE, Mass. — Biogen will name Michel Vounatsos its CEO, according to a Reuters report.

Vounatsos will succeed CEO George Scangos as early as this week, people close to the situation told the news outlet, asking not to be identified because the matter is not yet public. Biogen offered no immediate comment when contacted by Reuters.

Vounatsos serves as executive vice president and chief commercial officer at Biogen. He joined Biogen in 2016 after a 20-year career at Merck, where he most recently served as president, Primary Care Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit.

Scangos has served as CEO of Biogen since July 2010. From 1996 to July 2010, he served as president and CEO of drug discovery and development company Exelixis.